Senti Bio's 'Smart' Cell Therapy Offers New Hope for Deadly Leukemia

SOUTH SAN FRANCISCO, Calif. – February 11, 2026 – Senti Biosciences has reached a pivotal moment in its quest to treat one of the most aggressive blood cancers, announcing today the completion of enrollment for its Phase 1 clinical trial of SENTI-202. The novel cell therapy is being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML), a disease with a grim prognosis and limited effective treatment options.

The announcement signals a major step forward for the clinical-stage biotechnology company and its proprietary Gene Circuit platform. It follows a highly encouraging data presentation at the 2025 American Society of Hematology (ASH) Annual Meeting, where SENTI-202 demonstrated the ability to produce deep and lasting remissions in a heavily pretreated patient population, all while maintaining a favorable safety profile.

“The completion of enrollment in our Phase 1 trial represents a significant clinical milestone for our SENTI-202 program,” said Kanya Rajangam, M.D., Ph.D., Chief Medical Officer at Senti Bio, in a statement. “Importantly, the encouraging clinical data from this study provide a strong foundation as we actively design our pivotal program for SENTI-202 in AML, as well as potential indication expansion and later-stage clinical development.”

A New Generation of Programmable Medicine

At the heart of SENTI-202 is a sophisticated synthetic biology approach that sets it apart from earlier generations of cell therapies. Described as a "Logic Gated" off-the-shelf CAR-NK (Chimeric Antigen Receptor Natural Killer) cell therapy, it is engineered to function like a biological computer, making complex decisions to selectively destroy cancer cells while sparing healthy tissue.

This precision is achieved through three key components:

1. An 'OR' Gate: The therapy is armed with an activating receptor that recognizes two distinct targets commonly found on AML cells: CD33 and FLT3. By targeting either or both of these antigens, SENTI-202 is designed to mount a comprehensive attack against both mature leukemic blasts (which primarily express CD33) and the resilient leukemic stem cells (which often express FLT3) responsible for disease relapse.

2. A 'NOT' Gate: This is the therapy's crucial safety switch. The CAR-NK cells are also engineered with an inhibitory receptor that recognizes a protein called Endomucin (EMCN), which is selectively expressed on the surface of healthy hematopoietic stem and progenitor cells (HSPCs). If a SENTI-202 cell encounters a healthy stem cell, this 'NOT' gate overrides the 'kill' signal, even if that healthy cell expresses CD33 or FLT3. This innovation aims to prevent the severe bone marrow toxicity that has plagued other potent cell therapies, potentially widening the therapeutic window.

3. Calibrated-Release IL-15: To overcome another common hurdle in cell therapy—poor persistence—SENTI-202 is engineered to produce its own IL-15, a cytokine that promotes the survival, expansion, and activity of the CAR-NK cells after they are infused into the patient.

Because the NK cells are sourced from healthy donors, manufactured in advance, and cryopreserved, SENTI-202 is an "off-the-shelf" product, making it readily available for patients in need without the lengthy and complex manufacturing process associated with autologous (patient-derived) cell therapies.

Translating Science into Clinical Success

The true test of this innovative design lies in its clinical performance, and the data presented at the recent ASH conference provided compelling evidence of its potential. In a group of 20 heavily pretreated R/R AML patients, many of whom had failed multiple prior lines of therapy, SENTI-202 demonstrated significant anti-leukemic activity.

At the recommended Phase 2 dose, the therapy achieved a 50% Overall Response Rate (ORR) and a 42% rate of Complete Remission (CR) or Complete Remission with incomplete hematologic recovery (CRh). For a patient population where median survival is often measured in months, these numbers are notable. Even more significant was the depth of these responses: 100% of the complete remissions were Measurable Residual Disease (MRD) negative. Achieving MRD negativity means that highly sensitive tests could not detect any remaining cancer cells, a key indicator of a deep and potentially more durable remission.

The median duration of these complete remissions was 7.6 months, with some patients remaining in remission for nearly a year. This was all achieved with a well-tolerated safety profile. No dose-limiting toxicities were observed, and instances of cytokine release syndrome (CRS), a common side effect of cell therapies, were low-grade and resolved quickly.

These results are particularly striking given the dire landscape of R/R AML. Current options often involve intensive salvage chemotherapy with significant toxicity, and allogeneic stem cell transplant—the only potentially curative option—is not feasible for many patients. The emergence of a therapy that can induce deep, lasting remissions with a manageable safety profile represents a significant beacon of hope.

An Accelerated Path Forward

Bolstered by the positive Phase 1 results, Senti Bio is planning for rapid advancement. The company intends to meet with the U.S. Food and Drug Administration (FDA) in the first half of 2026 to discuss the design of a pivotal, registration-enabling study for SENTI-202 in R/R AML.

This path may be expedited by the Regenerative Medicine Advanced Therapy (RMAT) designation granted to SENTI-202 by the FDA. This designation is reserved for therapies that have shown potential to address unmet medical needs for serious conditions and provides benefits such as more frequent FDA interactions and eligibility for accelerated approval pathways. Combined with its existing Orphan Drug Designation, SENTI-202 is on a firm regulatory footing.

The company is also looking beyond R/R AML, evaluating potential expansion into treating newly diagnosed AML and pediatric AML, where the need for safer, more effective therapies is also acute. This clinical progress serves as a powerful validation of Senti Bio’s Gene Circuit platform, positioning the South San Francisco-based firm as a key player in the next wave of programmable medicines. With sufficient funding secured to support operations into 2026, the company appears well-equipped to advance its pioneering therapy toward the patients who desperately need it.